Cover Image

Biosimilars in Europe

This reprint examines regulatory, pricing and reimbursement issues related to the market access and uptake of off-patent biologics, biosimilars, next-generation biologics and competing innovative medicines in European countries.

Saved in:
Format: Online
Language:English
Published: MDPI - Multidisciplinary Digital Publishing Institute 2023
Subjects:
infliximab
etanercept
TNFα inhibitors
biologics
biosimilars
Germany
policies
incentives
uptake
market dynamics
biosimilar market
biosimilar/supply and distribution
biosimilar sustainability
Delphi technique
pricing
reimbursement
utilization
biosimilar
biological
information
education
communication
patient
Europe
adalimumab
biosimilarity assessment
quality attributes (QAs)
potentially critical quality attributes (pCQAs)
European public assessment reports (EPARs)
clinical governance
Spain
barriers
regulatory
review
approval
clinical
queries
regulatory science
budget impact analysis
savings
pharmaceutical spending
cost containment
reference biological
competitive market
Belgium
trastuzumab
intravenous
subcutaneous
HER2-positive breast cancer
drug costs
healthcare costs
cost simulation
tender
procurement
off-patent
award criteria
switching
interchangeability
sustainability
competition
n/a
thema EDItEUR::M Medicine and Nursing
thema EDItEUR::K Economics, Finance, Business and Management::KN Industry and industrial studies::KND Manufacturing industries
Online Access:ONIX_20230202_9783036565750_185
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

ONIX_20230202_9783036565750_185

Similar Items